We can’t show the full text here under this license.
Comparing how well and how safely different glucagon-like peptide 1 drugs treat type 2 diabetes
Updated
Abstract
Evidence from 12 studies involving 6213 patients indicates varying efficacy of glucagon-like peptide 1 receptor agonists (GLP-1RAs) on glycemic control.
- Once-weekly GLP-1 receptor agonists significantly reduced hemoglobin A1c levels compared to placebo.
- Semaglutide 2.0mg demonstrated the greatest glucose-lowering effect among the GLP-1RA regimens.
- Other effective regimens included Semaglutide 1.0mg, Dulaglutide 4.5mg, and several lower doses of Semaglutide and Dulaglutide.
- The GLP-1RA treatments showed a comparable safety profile regarding hypoglycemia.
- All long-acting GLP-1RAs, except PEX168, had lower rates of gastrointestinal events like diarrhea, nausea, and vomiting compared to placebo.
Simplified
Key numbers
−0.74%
Reduction with Semaglutide 2.0 mg
Standardized mean difference compared to placebo.
−5.51 kg
Weight Loss with Semaglutide 2.0 mg
Standardized mean difference compared to placebo.
3.91
Incidence of Hypoglycemia
Odds ratio compared to placebo.